Pipeline
Advancing novel precision therapeutics for serious muscle disease
Muscular Dystrophy
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced damage in dystrophinopathies including Becker and Duchenne.
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced damage in dystrophinopathies including Becker and Duchenne.
Sevasemten is an orally-administered first-in-class fast myosin inhibitor designed to preserve and protect dystrophic muscle against contraction-induced damage in dystrophinopathies including Becker and Duchenne.
Cardiovascular
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
EDG-7500 is a novel oral, selective, cardiac sarcomere modulator for the treatment of HCM.
EDG-15400 is a novel oral, selective, cardiac sarcomere modulator, for the treatment of HFpEF and other diseases of diastolic dysfunction
EDG-003
Undisclosed Target
Cardiometabolic
Preclinical
*Sevasemten, EDG-7500, EDG-15400, and other undisclosed cardiac sarcomeric agents are investigational therapies.
They are not approved in any territory, and their safety and effectiveness have not been established.
Is a clinical trial right for you?
We are currently conducting clinical trials in muscular dystrophies and severe cardiovascular disease.
